As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
A growing number of entities misrepresent themselves as scholarly journals for financial gain despite not meeting scholarly publishing standards.1,2 As editors and members of the International ...
New research from Wake Forest University School of Medicine suggests that living in a disadvantaged neighborhood is ...